Cencora Inc. (COR)
Cencora Inc. (COR) carries a ŷRobot AI score of 80 out of 100. The model's fair value estimate is $395.27, 10.0% above the last close of $359.19. The chart signal reads Sell.
| Metric | COR |
|---|---|
| AI score | 80 / 100 |
| Chart signal | Sell |
| Fair value estimate | $395.27 |
| Upside to fair value | 10.0% |
| Previous close | $359.19 |
| P/E | 25.28 |
| Price / sales | 0.20 |
| Market cap | $66.77B |
| EPS | 13.47 |
| Revenue growth | 10.0% |
| 1-year price change | 23.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about COR
Is COR overvalued or undervalued right now?
As of Nov 5, 2026, ŷRobot's fair-value model estimates Cencora Inc. (COR) at $395.27 against a last close of $359.19, implying 10.0% upside to the model's estimate.
Is COR's chart signal bullish or bearish?
The chart-signal model classifies COR as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is COR's ŷRobot AI score?
COR scores 80 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is COR stock expensive on P/E and P/S?
COR trades at 25.3 times earnings and 0.2 times sales as of Nov 13, 2026.
What does COR's seasonal forecast show?
ŷRobot's seasonal forecast curve for COR reads +1.7% at 30 days, +9.3% at 90 days, and +23.1% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is COR growing?
Cencora Inc.'s revenue growth is +10.0% and free-cash-flow growth is +3.3% on the latest reported figures.
COR chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.